Review





Similar Products

p gingivalis atcc 33277 results  (ATCC)
99
ATCC p gingivalis atcc 33277 results
P Gingivalis Atcc 33277 Results, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p gingivalis atcc 33277 results/product/ATCC
Average 99 stars, based on 1 article reviews
p gingivalis atcc 33277 results - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
scc results 200 000 cells ml or 100 000 cells ml for primiparous cows with different concentrations of several reference bacterial strains  (ATCC)
94
ATCC scc results 200 000 cells ml or 100 000 cells ml for primiparous cows with different concentrations of several reference bacterial strains
Scc Results 200 000 Cells Ml Or 100 000 Cells Ml For Primiparous Cows With Different Concentrations Of Several Reference Bacterial Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/scc results 200 000 cells ml or 100 000 cells ml for primiparous cows with different concentrations of several reference bacterial strains/product/ATCC
Average 94 stars, based on 1 article reviews
scc results 200 000 cells ml or 100 000 cells ml for primiparous cows with different concentrations of several reference bacterial strains - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
savanna hsv 1 2 vzv assay results  (DiaSorin Biotechnology)
94
DiaSorin Biotechnology savanna hsv 1 2 vzv assay results
Savanna Hsv 1 2 Vzv Assay Results, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/savanna hsv 1 2 vzv assay results/product/DiaSorin Biotechnology
Average 94 stars, based on 1 article reviews
savanna hsv 1 2 vzv assay results - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
sem eds results  (Hitachi Ltd)
99
Hitachi Ltd sem eds results
Sem Eds Results, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sem eds results/product/Hitachi Ltd
Average 99 stars, based on 1 article reviews
sem eds results - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
plasma p tau217 results  (Fujirebio Inc)
99
Fujirebio Inc plasma p tau217 results
Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
Plasma P Tau217 Results, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasma p tau217 results/product/Fujirebio Inc
Average 99 stars, based on 1 article reviews
plasma p tau217 results - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
plasma ptau217 results  (Fujirebio Inc)
99
Fujirebio Inc plasma ptau217 results
Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
Plasma Ptau217 Results, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasma ptau217 results/product/Fujirebio Inc
Average 99 stars, based on 1 article reviews
plasma ptau217 results - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
aio 48 sp qpcr system  (LabTurbo Biotech)
90
LabTurbo Biotech aio 48 sp qpcr system
Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
Aio 48 Sp Qpcr System, supplied by LabTurbo Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aio 48 sp qpcr system/product/LabTurbo Biotech
Average 90 stars, based on 1 article reviews
aio 48 sp qpcr system - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
genotyping assay results  (Transnetyx)
99
Transnetyx genotyping assay results
Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
Genotyping Assay Results, supplied by Transnetyx, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genotyping assay results/product/Transnetyx
Average 99 stars, based on 1 article reviews
genotyping assay results - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

Article Snippet: In conclusion, here we present cut‐points (0.153/0.422 pg/mL), derived against CSF amyloid status classification and validated against amyloid PET, to be used within the context of specialist memory clinic settings for the interpretation of Lumipulse (Fujirebio) plasma p‐tau217 results in individuals being evaluated for cognitive impairment.

Techniques: Clinical Proteomics, Derivative Assay

Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

Article Snippet: In conclusion, here we present cut‐points (0.153/0.422 pg/mL), derived against CSF amyloid status classification and validated against amyloid PET, to be used within the context of specialist memory clinic settings for the interpretation of Lumipulse (Fujirebio) plasma p‐tau217 results in individuals being evaluated for cognitive impairment.

Techniques: Concentration Assay, Clinical Proteomics, Analytical Sample Preparation, Centrifugation